Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 28 articles: HTML format

Single Articles

September 2025
1. SANTIAGO LR, Ladoukakis E, Scibior-Bentkowska D, Nedjai B, et al
   Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer.
   Int J Cancer. 2025 Sep 16. doi: 10.1002/ijc.70163.
   PubMed     Abstract available
   
   
   
2. CHOPRA R, Li H, Xie W, Lam DHT, et al
   Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.
   Int J Cancer. 2025 Sep 15. doi: 10.1002/ijc.70149.
   PubMed     Abstract available
   
   
   
3. LIN E, Garmo H, Beckmann K, Bratt O, et al
   Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons.
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70133.
   PubMed     Abstract available
   
   
   
4. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   PubMed     Abstract available
   
   
   August 2025
5. HAN Y, Li C, Sun J, Wu G, et al
   Comments on "CTHRC1 promotes bone metastasis in prostate cancer".
   Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70081.
   PubMed    
   
   
   July 2025
6. OKWOR UE, Raitanen J, Talala K, Tammela TLJ, et al
   Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial.
   Int J Cancer. 2025 Jul 17. doi: 10.1002/ijc.70026.
   PubMed     Abstract available
   
   
   
7. MUCHADEYI MT, Hao S, Hernandez-Villafuerte K, Khan SA, et al
   Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.
   Int J Cancer. 2025 Jul 16. doi: 10.1002/ijc.35513.
   PubMed     Abstract available
   
   
   June 2025
8. STITZ R, Stoiber F, Silye R, Rebhan E, et al
   Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.
   Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70019.
   PubMed     Abstract available
   
   
   
9. SAWADA Y, Kikugawa T, Onishi T, Arai O, et al
   CTHRC1 promotes bone metastasis in prostate cancer.
   Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70012.
   PubMed     Abstract available
   
   
   December 2024
10. SIECH C, de Angelis M, Jannello LMI, Di Bello F, et al
    Life expectancy in rare histological prostate cancer subtypes.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35323.
    PubMed     Abstract available
    
    
    
11. MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al
    Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
    Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279.
    PubMed     Abstract available
    
    
    October 2024
12. GRENVILLE ZS, Noor U, Rinaldi S, Gunter MJ, et al
    Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35208.
    PubMed     Abstract available
    
    
    September 2024
13. MOGHUL M, Tran A, Croft F, Kinsella N, et al
    The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
    Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169.
    PubMed     Abstract available
    
    
    July 2024
14. BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al
    Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Int J Cancer. 2024;155:314-323.
    PubMed     Abstract available
    
    
    June 2024
15. HUANG CY, Huang CP, Huang YY, Huang SK, et al
    Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
    Int J Cancer. 2024 Jun 26. doi: 10.1002/ijc.35040.
    PubMed     Abstract available
    
    
    
16. SEE AW, Conway P, Frydenberg M, Haxhimolla H, et al
    Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35052.
    PubMed     Abstract available
    
    
    April 2024
17. LUO Y, Yu J, Lin Z, Wang X, et al
    Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967.
    PubMed     Abstract available
    
    
    
18. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    PubMed     Abstract available
    
    
    March 2024
19. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    PubMed     Abstract available
    
    
    
20. LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al
    Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
    Int J Cancer. 2024;154:926-939.
    PubMed     Abstract available
    
    
    
21. ZHANG Y, Stopsack KH, Song M, Mucci LA, et al
    Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34898.
    PubMed     Abstract available
    
    
    February 2024
22. CARUANA M, Gulati R, Etzioni R, Barratt A, et al
    Benefits and harms of prostate specific antigen testing according to Australian guidelines.
    Int J Cancer. 2024;154:648-658.
    PubMed     Abstract available
    
    
    January 2024
23. SCHUURMAN MS, Lemmens VEPP, Portielje JEA, van der Aa MA, et al
    The cancer burden in the oldest-old: Increasing numbers and disparities-A nationwide study in the Netherlands, 1990 to 2019.
    Int J Cancer. 2024;154:261-272.
    PubMed     Abstract available
    
    
    
24. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available
    
    
    November 2023
25. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    PubMed     Abstract available
    
    
    
26. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    PubMed     Abstract available
    
    
    
27. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    PubMed     Abstract available
    
    
    October 2023
28. ALMURADOVA E, Seyyar M, Arak H, Tamer F, et al
    The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.